Drug candidate outperforms remdesivir as COVID-19 antiviral in cell assays
A compound called BOLD-100, which has shown efficacy against COVID-19 in pre-clinical trials, has now outperformed remdesivir in a cytopathic effect assay.
List view / Grid view
A compound called BOLD-100, which has shown efficacy against COVID-19 in pre-clinical trials, has now outperformed remdesivir in a cytopathic effect assay.
A drug screen using machine learning has identified hundreds of potential drugs that could be used to treat COVID-19, researchers say.
Rick Wagner of ZebiAI and Patrick Riley of Google Accelerated Science (GAS) discuss the development and benefits of a new machine learning drug discovery platform.
Small molecules named CS1 (bisantrene) and CS2 (brequinar) have been developed by researchers to suppress the growth of tumours and have shown promise in mouse models.
A group of small molecules called naphthalene-based PLpro inhibitors have been shown to block the activity of a SARS-CoV-2 protein, demonstrating potential as COVID-19 therapeutics.
Non-invasive imaging has played an increasing role in drug discovery and development processes. Nikki Withers spoke with Yochi Slonim, who discusses a novel technology that leverages FRET signals for the discovery of small molecule drugs that selectively control mRNA translation in a novel target space.
Researchers investigating telomere dieases such as dyskeratosis congenita have found lead compounds that reverse cellular ageing in mouse models of the condition.
The enterprise revealed that it has made its COVID-19 Drug Repurposing Database open-access to aid in the search for an effective therapeutic.
Researchers have developed two small molecules which target two components of the circadian rhythm and could be used to lengthen the body clock.
Researchers show Naphthyridine-Azaquinolone (NA) could be a possible future therapy able to slow the progression and improve the symptoms of Huntington’s disease.
Upregulating utrophin using small molecules could be a new therapeutic approach for Duchenne muscular dystrophy (DMD).
Research into the structure of the drug-integrin complex has enabled the creation of drugs which inhibit integrin as effectively as currently used compounds, without causing excessive bleeding.
Research identified a small molecule that targets the mRNA of α-synuclein and prevents the formation of the protein, an approach which could provide novel neurodegeneration therapies.
The G-protein coupled receptor Frizzled, implicated in diseases like cancer, can be targeted with small molecules which could provide the basis for anti-cancer therapeutics, according to researchers.
A new experimental drug was shown by researchers to restore natural brain rhythms in mouse models of Alzheimer’s and promote learning and memory.